Elizabeth C Jury

List of Publications by Year
in descending order

79 papers	2,950 citations	186265 28 h-index	175258 52 g-index
86 all docs	86 docs citations	86 times ranked	3860 citing authors

#	Article	IF	Citations
1	Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19396-19401.	7.1	244
2	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatology, The, 2020, 2, e594-e602.	3.9	200
3	Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T Cells. Immunity, 2012, 36, 477-490.	14.3	174
4	Altered lipid raftâ€“associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. Journal of Clinical Investigation, 2004, 113, 1176-1187.	8.2	156
5	Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. Journal of Clinical Investigation, 2014, 124, 712-724.	8.2	130
6	Statins for Atherosclerosis â€" As Good as It Gets?. New England Journal of Medicine, 2005, 352, 73-75.	27.0	125
7	Lipid rafts in T cell signalling and disease. Seminars in Cell and Developmental Biology, 2007, 18, 608-615.	5.0	115
8	Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 3955-3965.	6.7	114
9	Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2006, 177, 7416-7422.	0.8	114
10	Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice. Journal of Immunology, 2004, 173, 7641-7646.	0.8	113
11	Altered lipid raftâ€“associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. Journal of Clinical Investigation, 2004, 113, 1176-1187.	8.2	98
12	Regulation of T-cell receptor signalling by membrane microdomains. Immunology, 2004, 113, 413-426.	4.4	89
13	Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 1343-1354.	6.7	80
14	Lipid rafts and Tâ€lymphocyte function: Implications for autoimmunity. FEBS Letters, 2008, 582, 3711-3718.	2.8	75
15	Primary Human CD4+ T Cells Have Diverse Levels of Membrane Lipid Order That Correlate with Their Function. Journal of Immunology, 2011, 186, 3505-3516.	0.8	71
16	Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of SjÃ¶grenâ€™s syndrome. Rheumatology, 2016, 55, 1548-1555.	1.9	63
17	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and TÂcell metabolic checkpoint. Nature Communications, 2021, 12, 2814.	12.8	54
18	Autoantibodies and overlap syndromes in autoimmune rheumatic disease. Journal of Clinical Pathology, 2001, 54, 340-347.	2.0	53

#	Article	IF	Citations
19	Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatology, The, 2020, 2, e485-e496.	3.9	52
20	Abnormal CTLAâ€4 function in T cells from patients with systemic lupus erythematosus. European Journal of Immunology, 2010, 40, 569-578.	2.9	50
21	Monocyte NOTCH2 expression predicts IFN-Î² immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, .	5.0	46
22	Altered lipid raftâ€“associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 291-302.	6.7	44
23	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. Science Immunology, 2016, 1, .	11.9	44
24	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1140-1142.	0.9	40
25	Machine Learning Techniques for Personalised Medicine Approaches in Immune-Mediated Chronic Inflammatory Diseases: Applications and Challenges. Frontiers in Pharmacology, 2021, 12, 720694.	3.5	37
26	Transcriptional Regulation of T-Cell Lipid Metabolism: Implications for Plasma Membrane Lipid Rafts and T-Cell Function. Frontiers in Immunology, 2017, 8, 1636.	4.8	36
27	Statins: immunomodulators for autoimmune rheumatic disease?. Lupus, 2005, 14, 192-196.	1.6	31
28	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
29	Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. Journal of Clinical Investigation, 2022, 132, .	8.2	29
30	Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?. Frontiers in Endocrinology, 2021, 12, 639757.	3.5	27
31	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1446-1458.	2.4	26
32	Stratification of Patients With SjÃ¶grenâ€™s Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. Arthritis and Rheumatology, 2021, 73, 1626-1637.	5.6	25
33	T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective. Lupus, 2004, 13, 413-422.	1.6	24
34	Liver X receptors in immune cell function in humans. Biochemical Society Transactions, 2015, 43, 752-757.	3.4	24
35	Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNÎ². Frontiers in Immunology, 2020, 11, 1527.	4.8	24
36	Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. EBioMedicine, 2021, 65, 103243.	6.1	23

#	Article	IF	Citations
37	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. Journal of Dermatological Science, 2013, 71, 22-28.	1.9	22
38	Sex hormones drive changes in lipoprotein metabolism. IScience, 2021, 24, 103257.	4.1	21
39	LXR directly regulates glycosphingolipid synthesis and affects human CD4+ T cell function. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
40	New role for Agrin in T cells and its potential importance in immune system regulation. Arthritis Research and Therapy, 2010, 12, 205.	3.5	16
41	A negatively charged domain of LAT mediates its interaction with the active form of Lck. Molecular Membrane Biology, 2011, 28, 487-494.	2.0	14
42	Editorial: Immunogenicity of Proteins Used as Therapeutics. Frontiers in Immunology, 2020, 11, 614856.	4.8	14
43	Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2021, 22, 7619.	4.1	13
44	Agrin Signalling Contributes to Cell Activation and Is Overexpressed in T Lymphocytes from Lupus Patients. Journal of Immunology, 2007, 179, 7975-7983.	0.8	12
45	Analyzing T-Cell Plasma Membrane Lipids by Flow Cytometry. Methods in Molecular Biology, 2019, 1951, 209-216.	0.9	12
46	Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology, 2020, 59, 194-204.	1.9	11
47	Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk. Metabolites, 2022, 12, 3.	2.9	11
48	Manipulating membrane lipid profiles to restore T-cell function in autoimmunity. Biochemical Society Transactions, 2015, 43, 745-751.	3.4	10
49	Distinct localization of Tâ€ƒcell Agrin during antigen presentationâ€ƒâ€“â€ƒevidence for the expression of Agrin receptor(s) in antigenâ€presenting cells. FEBS Journal, 2012, 279, 2368-2380.	4.7	9
50	Low Percentage of Signal Regulatory Protein Î±/Î²+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. Frontiers in Immunology, 2018, 9, 2865.	4.8	9
51	A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases. Pediatric Rheumatology, 2021, 19, 47.	2.1	7
52	Treatment strategies for SjÃ¶grenâ€™s syndrome with childhood onset: a systematic review of the literature. Rheumatology, 2022, 61, 892-912.	1.9	7
53	The role of cholesterol metabolism in multiple sclerosis: From molecular pathophysiology to radiological and clinical disease activity. Autoimmunity Reviews, 2022, 21, 103088.	5.8	7
54	Could the expression of CD86 and FcÎ³RIIB on B cells be functionally related and involved in driving rheumatoid arthritis?. Arthritis Research and Therapy, 2010, 12, 133.	3.5	6

#	Article	IF	Citations
55	Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110026.	2.7	6
56	Barriers to translational research in SjÃ¶gren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease. Lancet Rheumatology, The, 2021, 3, e138-e148.	3.9	6
57	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. Lupus Science and Medicine, 2014, 1, e000013.	2.7	5
58	Challenges in Implementing Cardiovascular Risk Scores for Assessment of Young People With Childhood-Onset Autoimmune Rheumatic Conditions. Frontiers in Medicine, 2022, 9, 814905.	2.6	5
59	Comorbidity in young patients with juvenile systemic lupus erythematosus: how can we improve management?. Clinical Rheumatology, 2022, 41, 961-964.	2.2	5
60	Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk. Frontiers in Medicine, 0, 9, .	2.6	4
61	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. ACR Open Rheumatology, 2019, 1, 145-155.	2.1	3
62	Predicting long-term cardiometabolic risk: Do childhood metabolomic signatures hold the key?. EBioMedicine, 2021, 74, 103702.	6.1	2
63	O26.â€ƒSTRATIFICATION OF PATIENTS WITH JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS USING IMMUNE AND METABOLIC PHENOTYPING. Rheumatology, 2017, 56, .	1.9	1
64	E083â€ƒDesigning a diet interventional study for autoimmune rheumatic disease: asking patients what they think. Rheumatology, 2019, 58, .	1.9	1
65	Self-perceived disease activity was the strongest predictor of COVID-19 pandemic-related concerns in young people with autoimmune rheumatic diseases, irrespective of their gender, with females reporting higher concerns. Rheumatology Advances in Practice, 2022, 6, rkac031.	0.7	1
66	O37â€ƒComplex immunophenotyping stratifies patients with primary and secondary SjÃ¶grenâ€™s syndrome into distinct clinically relevant groups with potential therapeutic implications. Rheumatology, 2018, 57, .	1.9	0
67	O30â€ƒThe immunopathogenesis of juvenile-onset SLE could be associated with altered immune cell plasma membrane lipids and lipoprotein metabolism. Rheumatology, 2018, 57, .	1.9	0
68	254â€ƒTh17 cells are increased in adult dermatomyositis: a developing immune signature for the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
69	E024â€ƒInvariant natural killer T cells in RA and CVD. Rheumatology, 2019, 58, .	1.9	0
70	E084â€ƒValidation of complex immunophenotyping stratification of patients with lupus and SjÃ¶grenâ€™s syndrome with therapeutic potential. Rheumatology, 2019, 58, .	1.9	0
71	E089â€ƒCardiovascular disease in SLE: what do patients think about using diet as a therapeutic?. Rheumatology, 2019, 58, .	1.9	0
72	AB0229â€…RELATIVE MONOCYTE SUBSET DIFFERENCES BETWEEN JUVENILE- AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0

#	Article	IF	Citations
73	THU0722-HPRâ€…DESIGNING A DIET INTERVENTIONAL STUDY FOR AUTOIMMUNE RHEUMATIC DISEASE: ASKING PATIENTS WHAT THEY THINK. , 2019, , .		0
74	THU0723-HPRâ€…WHAT DO SJÃ–GRENâ€™S SYNDROME PATIENTS THINK ABOUT RESEARCH?. , 2019, , .		0
75	EP35â€ƒWhat do patients with lupus know about cardiovascular risk: could dietary modification be a promising therapeutic?. Rheumatology, 2020, 59, .	1.9	0
76	P122â€…What do patients with lupus and SjÃ¶grenâ€™s syndrome know about cardiovascular risk?. , 2020, , .		0
77	P126â€…Tolerability, efficacy and adherence: what do lupus patients think about treatment?. , 2020, , .		0
78	P062â€ƒCOVID-19 hyperinflammation can be predicted using routine clinical laboratory markers. Rheumatology, 2022, 61, .	1.9	0
79	CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities. Frontiers in Medicine, 0, 9, .	2.6	0